Literature DB >> 11063292

KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases.

S Fukaya1, H Oshima, K Kato, Y Komatsu, H Matsumura, K Ishii, H Miyama, T Nagai, I Tanaka, A Mizutani, M Katayama, S Yoshida, K Torikai.   

Abstract

The objective of this study was to determine the role of serum KL-6 levels as a marker for the activity of interstitial pneumonia in patients with connective tissue diseases. The serum concentrations of KL-6, a glycoprotein produced mainly by pulmonary type II epithelial cells, were measured in 21 patients with connective tissue disease. The activity of interstitial pneumonia was compared with the associated serum KL-6 concentrations. Serum KL-6 concentrations in patients with interstitial pneumonia were significantly higher than those in the controls. Among patients with active interstitial pneumonia, serum KL-6 concentrations following the treatment (after improvement) were significantly lower than the pretreatment values. The extent of the pulmonary fibrosis correlated positively with the serum KL-6 concentrations during the inactive phase of the interstitial pneumonia. These results suggest that sequential measurement of serum KL-6 levels is a new and useful means for the evaluation of interstitial pneumonia in patients with connective tissue diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063292     DOI: 10.1007/s002960000064

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  7 in total

1.  Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.

Authors:  Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Mio Kawaguchi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy.

Authors:  Yosuke Matsuno; Hiroaki Satoh; Hiroichi Ishikawa; Takahide Kodama; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

4.  High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia.

Authors:  H Ishii; H Mukae; J Kadota; H Kaida; T Nagata; K Abe; S Matsukura; S Kohno
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

Review 5.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

6.  Blood KL-6 predicts prognosis in primary Sjögren's syndrome-associated interstitial lung disease.

Authors:  Yun Jae Kim; Jooae Choe; Su-Jin Moon; Jin Woo Song
Journal:  Sci Rep       Date:  2022-03-29       Impact factor: 4.379

7.  Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Hongying Zhang; Lizhou Chen; Luling Wu; Jinbao Huang; Hongyan Li; Xinhang Wang; Heng Weng
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.